Genome-Wide Association Studies (GWAS) breast cancer susceptibility loci in Arabs: susceptibility and prognostic implications in Tunisians.

Abstract:

:Genome-wide Association Studies (GWAS) revealed novel genetic markers for breast cancer susceptibility. But little is known about the risk factors and molecular events associated with breast cancer in Arab Population. Therefore, we designed a broad study to investigate the susceptibility and prognostic implications of the GWAS breast cancer loci in the Tunisian population. In a cohort of 640 unrelated patients with breast cancer and 371 healthy control subjects, we characterized the variation of 9 single nucleotide polymorphisms (SNPs), namely rs1219648, rs2981582; rs8051542, rs12443621, and rs3803662; rs889312; rs3817198; rs13387042 and rs13281615. Only 5 out of 9 GWAS breast cancer loci were found to be significantly associated with breast cancer in Tunisians: The rs1219648 (G vs. A allele: OR = 1.36, P = 1 × 10(-3)) and rs2981582 (A vs. G allele: OR = 1.55, P = 3 × 10(-6)) of FGFR2 gene; the rs8051542 of the TNRC9 gene (T vs. C allele: OR = 1.40, P = 4 × 10(-4)); the rs889312 of the MAP3K1 gene (C vs. A allele: OR = 1.33, P = 3 × 10(-3)) and the rs13281615 located on 8q24 (G vs. A allele: OR = 1.21, P = 0.03). Homozygous variant genotypes of rs2981582 were strongly related to lymph node negative breast cancer (OR = 3.33, P = 6 × 10(-7)) and the minor allele of rs2981582 was associated with increased risk of ER+ tumors (OR = 1.57, P = 0.02; OR = 2.15, P = 0.001, for heterozygous and homozygous variant genotypes, respectively) and increased risk of distant metastasis development (OR = 2.30, P = 4 × 10(-3); OR = 3.57, P = 6 × 10(-5), for heterozygous and homozygous variant genotypes, respectively) in a dose dependent manner. The association for rs8051542 was stronger for high-grade SBR tumors (OR = 2.54, P = 2 × 10(-4)). GG genotype of rs13387042 on 2q35 showed a significant association with the risk of developing distant metastasis (OR = 1.94, P = 0.02). The G allele of rs1219648 in FGFR2 and the A allele of rs13387042 on 2q35 indicated a better prognosis by showing a significantly higher overall survival rates (P = 0.013 and P = 0.005, respectively). In conclusion, GWAS breast cancer FGFR2, TNRC9, MAP3K1, and 8q24 loci are associated with an increased risk of breast cancer and genetic variation in FGFR2 gene may predict the aggressiveness of breast cancer in Tunisians.

authors

Shan J,Mahfoudh W,Dsouza SP,Hassen E,Bouaouina N,Abdelhak S,Benhadjayed A,Memmi H,Mathew RA,Aigha II,Gabbouj S,Remadi Y,Chouchane L

doi

10.1007/s10549-012-2202-6

subject

Has Abstract

pub_date

2012-10-01 00:00:00

pages

715-24

issue

3

eissn

0167-6806

issn

1573-7217

journal_volume

135

pub_type

杂志文章
  • Validation of the 8th AJCC prognostic staging system for breast cancer in a population-based setting.

    abstract:OBJECTIVES:To validate the newly proposed American Joint Committee on Cancer (AJCC) prognostic staging system for breast cancer. METHODS:Surveillance, epidemiology, and end results (SEER) database (2010-2014) was accessed. Cumulative incidence function was conducted (through assessment of sub-distribution hazard) acco...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-017-4577-x

    authors: Abdel-Rahman O

    更新日期:2018-02-01 00:00:00

  • Potentiation of cytotoxic therapies by TNP-470 and minocycline in mice bearing EMT-6 mammary carcinoma.

    abstract::The ability of the antiangiogenic agents TNP-470 and minocycline, singly or in combination, to potentiate the antitumor effects of several cytotoxic therapies was assessed in the murine EMT-6 mammary carcinoma as well as in two drug resistant sublines of that tumor designated EMT-6/CTX and EMT-6/CDDP. The antiangiogen...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF00666043

    authors: Teicher BA,Holden SA,Dupuis NP,Kakeji Y,Ikebe M,Emi Y,Goff D

    更新日期:1995-01-01 00:00:00

  • Desferri-exochelin induces death by apoptosis in human breast cancer cells but does not kill normal breast cells.

    abstract::A major goal of cancer chemotherapy is the identification of cytotoxic compounds that are highly selective for cancer cells. We describe here one such compound - a novel iron chelator, desferri-exochelin 772SM. This desferri-exochelin has unique chemical and pharmacological properties, including extremely high iron bi...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1012211828319

    authors: Pahl PM,Horwitz MA,Horwitz KB,Horwitz LD

    更新日期:2001-09-01 00:00:00

  • Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial.

    abstract::In the context of neoadjuvant therapy (NT) for breast cancer patients, different targeted therapy approaches are currently evaluated in clinical trials. Serum markers could help to monitor and optimize such treatment strategies. We investigated human epidermal growth factor receptor 2 serum (sHER2) levels in 175 breas...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1007/s10549-010-1030-9

    authors: Witzel I,Loibl S,von Minckwitz G,Mundhenke C,Huober J,Hanusch C,Henschen S,Hauschild M,Lantzsch T,Tesch H,Latos K,Just M,Hilfrich J,Barinoff J,Eulenburg CZ,Roller M,Untch M,Müller V

    更新日期:2010-09-01 00:00:00

  • Pharmacokinetics of sterically stabilized hexadecylphosphocholine liposomes versus conventional liposomes and free hexadecylphosphocholine in tumor-free and human breast carcinoma bearing mice.

    abstract::The pharmacokinetics of free and different liposomal formulations of hexadecylphosphocholine (HPC) was investigated in tumor-bearing (human mammary tumor MaTu) and tumor-free mice after intravenous and intraperitoneal administration. The levels of HPC were evaluated at different times in serum, normal tissues, and tum...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1006224611505

    authors: Arndt D,Zeisig R,Fichtner I,Teppke AD,Fahr A

    更新日期:1999-11-01 00:00:00

  • The financial impact and drivers of hospital charges in contralateral prophylactic mastectomy and reconstruction: a Nationwide Inpatient Sample hospital analysis.

    abstract:PURPOSE:Rates of contralateral prophylactic mastectomy (CPM) have increased over the last decade; it is important for surgeons and hospital systems to understand the economic drivers of increased costs in these patients. This study aims to identify factors affecting charges in those undergoing CPM and reconstruction. ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-017-4315-4

    authors: Bucknor A,Chattha A,Ultee K,Wu W,Kamali P,Bletsis P,Chen A,Lee BT,Cronin C,Lin SJ

    更新日期:2017-09-01 00:00:00

  • Accuracy of unidimensional and volumetric ultrasound measurements in predicting good pathological response to neoadjuvant chemotherapy in breast cancer patients.

    abstract::Pathological complete response (pCR) is an important predictor of long-term survival in patients with breast cancer receiving neoadjuvant chemotherapy (NAC). At present, the accuracy of traditional radiological assessments during treatment in predicting pCR is poor. Unidimensional and 3D volumetric ultrasound measurem...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-011-1454-x

    authors: Gounaris I,Provenzano E,Vallier AL,Hiller L,Iddawela M,Hilborne S,Taylor K,Britton P,Earl HM,Sinnatamby R

    更新日期:2011-06-01 00:00:00

  • Effect of chemotherapy on survival in metastatic breast cancer.

    abstract::In order to assess the impact of modern combination chemotherapy on overall survival of metastatic breast cancer patients, we retrospectively analysed survival data of those patients who presented with breast cancer and developed metastases at our clinic from 1971-78 inclusive. Our results indicate a trend towards imp...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF01806751

    authors: Paterson AH,Szafran O,Cornish F,Lees AW,Hanson J

    更新日期:1981-01-01 00:00:00

  • Followup after 11 years--update of mortality results in the Stockholm mammographic screening trial.

    abstract::Results from several randomised mammography screening trials have shown that it is possible to reduce mortality in breast cancer by mammographic screening at least for women above 50 years of age. The purpose of this article is to present data on mortality in breast cancer in study and control groups of the Stockholm ...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1023/a:1005872617944

    authors: Frisell J,Lidbrink E,Hellström L,Rutqvist LE

    更新日期:1997-09-01 00:00:00

  • The additional cancer yield of clinical breast examination in screening of women at hereditary increased risk of breast cancer: a systematic review.

    abstract::Women at hereditary increased risk of breast cancer are subjected to frequent clinical breast examination (CBE) and radiological evaluation of the breasts. This review appraises the additional cancer yield by CBE in screening of women at increased risk of breast cancer who are also subjected to frequent radiological e...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1007/s10549-014-3074-8

    authors: Roeke T,van Bommel AC,Gaillard-Hemmink MP,Hartgrink HH,Mesker WE,Tollenaar RA

    更新日期:2014-08-01 00:00:00

  • Pnck overexpression in HER-2 gene-amplified breast cancer causes Trastuzumab resistance through a paradoxical PTEN-mediated process.

    abstract::The gene for Pregnancy Up-regulated Non-ubiquitous Calmodulin Kinase (Pnck), a novel calmodulin kinase, is expressed in roughly one-third of human breast tumors, but not in adjoining normal tissues. Pnck alters EGFR stability and function, prompting this study to determine if Pnck expression has implications for HER-2...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-015-3337-z

    authors: Deb TB,Zuo AH,Barndt RJ,Sengupta S,Jankovic R,Johnson MD

    更新日期:2015-04-01 00:00:00

  • Medical costs associated with metastatic breast cancer in younger, midlife, and older women.

    abstract:PURPOSE:We estimated average medical costs due to metastatic breast cancer (mBC) among younger (aged 18-44), midlife (aged 45-64), and older women (aged 65 and older) by phase of care: initial, continuing, and terminal. METHODS:We used 2003-2014 North Carolina cancer registry data linked with administrative claims fro...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-020-05654-x

    authors: Trogdon JG,Baggett CD,Gogate A,Reeder-Hayes KE,Rotter J,Zhou X,Ekwueme DU,Fairley TL,Wheeler SB

    更新日期:2020-06-01 00:00:00

  • Evaluation and management of insomnia in women with breast cancer.

    abstract:PURPOSE:Insomnia is a common issue among patients with breast cancer with a potentially devastating impact on quality of life. It can be caused or exacerbated by multiple disease and treatment-related factors. Despite the prevalence and impact of insomnia, it is rarely addressed systematically in the oncology clinic. W...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1007/s10549-020-05635-0

    authors: Kwak A,Jacobs J,Haggett D,Jimenez R,Peppercorn J

    更新日期:2020-06-01 00:00:00

  • Pro-inflammatory cytokines and growth factors in human milk: an exploratory analysis of racial differences to inform breast cancer etiology.

    abstract:BACKGROUND:Analysis of cytokines and growth factors in human milk offers a noninvasive approach for studying the microenvironment of the postpartum breast, which may better reflect tissue levels than testing blood samples. Given that Black women have a higher incidence of early-onset breast cancers than White women, we...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-018-4907-7

    authors: Murphy J,Pfeiffer RM,Lynn BCD,Caballero AI,Browne EP,Punska EC,Yang HP,Falk RT,Anderton DL,Gierach GL,Arcaro KF,Sherman ME

    更新日期:2018-11-01 00:00:00

  • Erratum to: Low expression of ULK1 is associated with operable breast cancer progression and is an adverse prognostic marker of survival for patients.

    abstract::Erratum to: Breast Cancer Res Treat (2012),134:549–560,DOI 10.1007/s10549-012-2080-y. In the original publication of the article, Fig. 5c was published incorrectly. The authors apologize for this error and the correct Fig. 5c is given below. ...

    journal_title:Breast cancer research and treatment

    pub_type: 已发布勘误

    doi:10.1007/s10549-016-3703-5

    authors: Tang J,Deng R,Luo RZ,Shen GP,Cai MY,Du ZM,Jiang S,Yang MT,Fu JH,Zhu XF

    更新日期:2016-04-01 00:00:00

  • Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis.

    abstract::Inflammatory breast cancer (IBC) is a rare and aggressive disease. Previous studies have shown that among patients with stage III breast cancer, IBC is associated with a worse prognosis than noninflammatory breast cancer (non-IBC). Whether this difference holds true among patients with stage IV breast cancer has not b...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-015-3436-x

    authors: Fouad TM,Kogawa T,Liu DD,Shen Y,Masuda H,El-Zein R,Woodward WA,Chavez-MacGregor M,Alvarez RH,Arun B,Lucci A,Krishnamurthy S,Babiera G,Buchholz TA,Valero V,Ueno NT

    更新日期:2015-07-01 00:00:00

  • CCND1 G870A polymorphism contributes to breast cancer susceptibility: a meta-analysis.

    abstract::Cyclin D1 (CCND1), a key cell cycle regulatory protein that governs the cell cycle progression from G1 to S phase, can promote cell proliferation or induce growth arrest and apoptosis. Since the identification of a well-characterized functional polymorphism, G870A in exon 4 of CCND1, several molecular epidemiological ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,meta分析

    doi:10.1007/s10549-008-0195-y

    authors: Lu C,Dong J,Ma H,Jin G,Hu Z,Peng Y,Guo X,Wang X,Shen H

    更新日期:2009-08-01 00:00:00

  • Health-related quality of life before and after a breast cancer diagnosis.

    abstract::While many reports describe health-related quality of life (QOL) among breast cancer survivors, few compare QOL before and after diagnosis and whether changes in QOL substantially differ from changes experienced by all women during aging. QOL was examined in a cohort of female residents of Beaver Dam, Wisconsin, aged ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-007-9653-1

    authors: Trentham-Dietz A,Sprague BL,Klein R,Klein BE,Cruickshanks KJ,Fryback DG,Hampton JM

    更新日期:2008-05-01 00:00:00

  • PACAP(6-38) is a PACAP receptor antagonist for breast cancer cells.

    abstract::The effects of pituitary adenylate cyclase activating polypeptide (PACAP) analogs were investigated using breast cancer cells. 125I-PACAP-27 bound with high affinity (Kd = 5 nM) to T47D cells (Bmax = 29,000 per cell). Specific 125I-PACAP-27 binding was inhibited half maximally by PACAP-27, PACAP-38, PACAP(6-38) and PA...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1006262611290

    authors: Leyton J,Gozes Y,Pisegna J,Coy D,Purdom S,Casibang M,Zia F,Moody TW

    更新日期:1999-07-01 00:00:00

  • High risk of breast cancer in women with biallelic pathogenic variants in CHEK2.

    abstract:PURPOSE:Compared to breast cancer risk genes such as BRCA2, ATM, PALB2, and NBN, no defined phenotype is currently associated with biallelic pathogenic variants (PVs) in CHEK2. This study compared the prevalence of breast and other cancers in women with monoallelic and biallelic CHEK2 PVs. METHODS:CHEK2 PV carriers we...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-020-05543-3

    authors: Rainville I,Hatcher S,Rosenthal E,Larson K,Bernhisel R,Meek S,Gorringe H,Mundt E,Manley S

    更新日期:2020-04-01 00:00:00

  • A phase II trial of cyclophosphamide, epirubicin and vinorelbine in the treatment of advanced breast cancer.

    abstract:BACKGROUND:Vinorelbine (Navelbin; N) has proven to be active in patients with advanced breast cancer (ABC) and cyclophosphamide (C) and epirubicin (Epiadriamycin: E) are still among the main cytostatic agents against this tumor. On this basis was carried out a study to determine the activity and toxicity of the combina...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1023/a:1006477109230

    authors: Esteban E,de Sande G,Puertas J,Fra J,Palacio I,Vieitez JM,Fernández JL,Muñiz I,Modollel A,Carrasco J,Sala M,Lacave AJ

    更新日期:2000-07-01 00:00:00

  • Concordance with BRCA1/2 testing guidelines among women in The Health of Women (HOW) Study®.

    abstract:PURPOSE:To evaluate factors associated with compliance to the National Comprehensive Cancer Network (NCCN) guidelines for BRCA1/2 testing and identify groups who are at risk of under- and over-use of BRCA1/2 testing. METHODS:Data included 20,758 women from Dr. Susan Love Research Foundation's The Health of Women (HOW)...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-018-5035-0

    authors: Silver MI,Klein W,Samimi G,Minasian L,Loud J,Roberts MC

    更新日期:2019-02-01 00:00:00

  • A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer.

    abstract::Heat shock protein 90 (Hsp90) facilitates maturation and stability of HER2. Combining an Hsp90 inhibitor and trastuzumab has demonstrated anti-tumor effects in patients with HER2+ breast cancer. Adults with measurable, locally advanced or metastatic HER2+ breast cancer and prior trastuzumab treatment were enrolled in ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,多中心研究

    doi:10.1007/s10549-013-2510-5

    authors: Modi S,Saura C,Henderson C,Lin NU,Mahtani R,Goddard J,Rodenas E,Hudis C,O'Shaughnessy J,Baselga J

    更新日期:2013-05-01 00:00:00

  • Age-of-onset heterogeneity in hereditary breast cancer: minimal clues for diagnosis.

    abstract::Knowledge of the family history of cancer may significantly influence diagnosis and surgical management. Hereditary breast cancer (HBC) is common and accounts for approximately 9% of the total breast cancer burden. The pattern of HBC's natural history, including age of onset, increased incidence of bilaterality, integ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF01811240

    authors: Lynch HT,Conway T,Fitzgibbons R Jr,Schreiman J,Watson P,Marcus J,Fitzsimmons ML,Lynch JF

    更新日期:1988-12-01 00:00:00

  • Prognostic value of HER2 status on circulating tumor cells in advanced-stage breast cancer patients with HER2-negative tumors.

    abstract:PURPOSE:Discordance between HER2 expression in tumor tissue (tHER2) and HER2 status on circulating tumor cells (cHER2) has been reported. It remains largely underexplored whether patients with tHER2-/cHER2+ can benefit from anti-HER2 targeted therapies. METHODS:cHER2 status was determined in 105 advanced-stage patient...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-020-05662-x

    authors: Wang C,Mu Z,Ye Z,Zhang Z,Abu-Khalaf MM,Silver DP,Palazzo JP,Jagannathan G,Fellin FM,Bhattacharya S,Jaslow RJ,Tsangaris TN,Berger A,Neupane M,Cescon TP,Lopez A,Yao K,Chong W,Lu B,Myers RE,Hou L,Wei Q,Li B,Cri

    更新日期:2020-06-01 00:00:00

  • Quality of life in women with recurrent breast cancer.

    abstract::Although the psychosocial concomitants of early-stage breast cancer have been well-documented, the relationship between cancer recurrence and quality of life remains less clear. We conducted a prospective, longitudinal study in order to clarify the relationship between recurrent cancer and quality of life, and to dete...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1023/a:1006172024218

    authors: Bull AA,Meyerowitz BE,Hart S,Mosconi P,Apolone G,Liberati A

    更新日期:1999-03-01 00:00:00

  • Association between financial burden and adjuvant hormonal therapy adherence and persistent use for privately insured women aged 18-64 years in BCBS of Texas.

    abstract:PURPOSE:The objective of this study is to understand an impact of financial burden on the adjuvant hormonal therapy (AHT) adherence and persistence for insured women aged 18-64 with early breast cancer in Texas. METHODS:We conducted a retrospective cohort study using claims data for population insured by Blue Cross Bl...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-018-4704-3

    authors: Kim J,Rajan SS,Du XL,Franzini L,Giordano SH,Morgan RO

    更新日期:2018-06-01 00:00:00

  • The expression of gene transcripts of telomere-associated genes in human breast cancer: correlation with clinico-pathological parameters and clinical outcome.

    abstract:BACKGROUND:Telomerase is a ribonucleoprotein enzyme that synthesises telomeres in human germ cells, embryogenesis and in cancer, maintaining chromosomal length, stability and cellular immortality. The hTERT gene is the rate-limiting determinant of telomerase reactivation during immortalization and malignant transformat...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-007-9622-8

    authors: Salhab M,Jiang WG,Newbold RF,Mokbel K

    更新日期:2008-05-01 00:00:00

  • Diet and risk for breast cancer recurrence and survival.

    abstract::Dietary factors may influence the risk for breast cancer and also the prognosis following diagnosis and treatment. The aim of this study was to assess whether self-reported prediagnosis diet or other patient factors associated with breast cancer incidence were predictive of recurrence and survival. Patients (n = 149) ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1006190820231

    authors: Saxe GA,Rock CL,Wicha MS,Schottenfeld D

    更新日期:1999-02-01 00:00:00

  • Refinement of breast cancer risk prediction with concordant leading edge subsets from prognostic gene signatures.

    abstract::Several prognostic signatures have been identified for breast cancer. However, these signatures vary extensively in their gene compositions, and the poor concordance of the risk groups defined by the prognostic signatures hinders their clinical applicability. Breast cancer risk prediction was refined with a novel appr...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-014-3104-6

    authors: Huang CC,Tu SH,Lien HH,Huang CS,Huang CJ,Lai LC,Tsai MH,Chuang EY

    更新日期:2014-09-01 00:00:00